AIDS-Related Mycoses: Current progress in the field and future priorities


1 Fungal Pathogens Laboratory, National Heart and Lung Institute, Imperial College London, SW7 2AY UK
2 Institute of Infection and Immunity, St. George’s University of London, London SW17 0RS3
3 Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory, 7925, Cape Town, South Africa
4 MRC Centre for Medical Mycology, Aberdeen Fungal Group, University of Aberdeen, Institute of Medical Sciences, Foresterhill, Aberdeen, AB25 2ZD, UK
5 Department of Microbiology and Immunology, University of Minnesota, Minneapolis, Minnesota, 55455

*Corresponding Author
Email: d.armstrong@imperial.ac.uk
Tel: +447790500385

Abstract
Opportunistic fungal infections continue to take an unacceptably heavy toll on the most disadvantaged living with HIV-AIDS, and are a major driver for HIV-related deaths. At the second EMBO AIDS-Mycoses Workshop, clinicians and scientists from around the world reported current progress and key priorities for improving outcomes from HIV-related mycoses.

Key words
HIV; AIDS; fungal infection; mortality; translational research; immunity

Global burden of HIV-related fungal disease
Whilst many fungi cause low grade superficial infections, these microorganisms are a major cause of high-mortality invasive infections in immunocompromised individuals[1]. Advanced HIV infection continues to be a major driver for invasive fungal diseases, despite the global scale-up of antiretroviral therapies (ART)[1]. Defining the global burden of fungal diseases presents a major challenge, as they are often insidious in nature, and there are intrinsic challenges in their diagnosis, as well as a global lack of capacity for fungal diagnostics[1]. Best estimates suggest there are up to a million invasive fungal infections per annum related to HIV-AIDS (primarily cryptococcosis, pneumocystosis, histoplasmosis, and talaromycosis (formerly penicilliosis)), with a consequential mortality of up to 500,000 per annum [2]. This places HIV-related fungal disease at
nearly the same level of mortality as other major infectious diseases such as malaria and tuberculosis[3, 4]. Current case fatality rates for cryptococcal meningitis vary between 30% and 70% for patients diagnosed and treated in sub-Saharan Africa[5, 6]. Recent data from the Amazon region for HIV-associated histoplasmosis indicates a 50% overall mortality rate at 1 year[7]. Studies in Uganda indicate on overall mortality of around 20% for HIV-related Pneumocystis pneumonia[8], and a mortality rate of 28% for HIV-associated talaromyces in Viet Nam[9]. In addition, oral candidiasis is very common and associated with a high degree of morbidity if untreated[1].

The Joint United Nations Programme on HIV/AIDS (UNAIDS) has established an ambitious treatment target known as 90-90-90 to control the AIDS epidemic(ii). But even if these targets are reached, there will still be a substantial burden of fungal disease in patients who present for care late or disengage from or fail ART. Despite this, fungal disease has not had the same level of focus from the global community, although as a result of recent efforts from the medical mycology community, we hope this is now changing.

At the inaugural meeting of the EMBO AIDS-Mycoses Working Group in Cape Town, South Africa in July 2013, 5 key goals were identified to improve outcomes from these deadly diseases:

2. Better laboratory and point-of-care testing.
3. Improved access to existing drugs.
4. Expansion of capacity for medical mycology training.
5. Increased funding for development of diagnosis, treatment and implementation programmes, especially in resource-poor settings.

Recent progress in the field

As part of ongoing efforts to stem the tide of fungal disease, over 100 researchers spearheading the battle against HIV-related fungal diseases in Africa, Asia, North and South America, Europe and Australasia met at the 2nd EMBO AIDS-Mycoses Workshop for three days in July 2016 in Cape Town, South Africa, to discuss current progress in the field and future priorities.

The workshop was notable for the geographic breadth of participants, as well as excellent coverage for all the major HIV-related fungal diseases. The major topics discussed were epidemiology and public health, diagnostics, host-pathogen interactions, immunology, drug resistance, treatment strategies, new antifungal drugs, and vaccines. Detailed updates were given on epidemiology and public health aspects of the major AIDS-related mycoses including cryptococcosis, histoplasmosis, talaromyces and pneumocystosis. In addition, newly recognized HIV-associated invasive fungal infections due to *Emmonsia* spp. (recently renamed *Emergomyces*) were highlighted. These infections appear to be unique to Southern Africa, and the clinical presentation mimics disseminated histoplasmosis. A notable observation was that whilst antiretroviral roll out appears to have had some impact on the incidence of cryptococcal meningitis in recent years, half of all cases occur after ART has been established[10]. When taken in the context of the global failure to reduce new HIV infections, emerging HIV drug resistance and challenges in retaining patients in ART care in resource-limited settings, it is clear that the ongoing epidemic of cryptococcal meningitis will be sustained. The high rates of HIV-associated infection and mortality from histoplasmosis in Latin America and talaromyces in South and South East Asia were also highlighted[9, 11]. Key highlights in fundamental research in AIDS-related mycoses included genomics-based studies of cryptococcal evolution and resistance in the host, a number of studies detailing aspects of metabolic adaptation of *Cryptococcus neoformans* and *Talaromyces marneffei* in the host, and descriptions of the latest discoveries in understanding the innate and adaptive immune responses to *Pneumocystis* spp.

A number of advances in the development and implementation of point-of-care-based testing (POCT) strategies were highlighted during the meeting. In particular, there has been enormous progress with the implementation of cryptococcal lateral flow device-based screening programmes
in sub-Saharan Africa. South Africa has recently implemented national reflex laboratory screening
with a projected 250 000 persons estimated to screened per annum[12]. The strategy of treating
antigen-positive patients reduces the likelihood of future cryptococcal meningitis[13]. Further
progress was also reported with the development of rapid tests for Talaromyces marneffei and
Histoplasma capsulatum infection.

Access to currently available antifungal medicines as well as the development of novel antifungal
drugs is an urgent priority, due to the limited drug classes and emerging resistance to triazoles.
Planned recruitment to the AMBITION study was outlined (intermittent high dose AmBisome
[liposomal amphotericin B] on a high dose fluconazole backbone for cryptococcal meningitis
induction therapy in sub-Saharan Africa), as well as current Phase 1/2 studies for VT-1129, a new
oral agent for cryptococcal disease, progress of the ACTA trial (oral fluconazole plus flucytosine or
one week amphotericin B-based therapy versus two weeks amphotericin B-based therapy) and the
ASTRO trial (Adjunctive Sertraline for the Treatment of HIV-associated cryptococcal meningitis).
There continues to be inadequate access to fluconosine, amphotericin B and itraconazole in
countries with major burdens of either cryptococcal meningitis or endemic mycoses. The
emergence of triazole resistance in both Cryptococcus neoformans and Aspergillus fumigatus was
also discussed[14, 15]. Notable progress has been made in understanding the genetic basis for the
emergence of cryptococcal hetero-resistance during therapy, and combination antifungal strategies
to limit this.

Advocacy for fungal diseases continues to gather pace, through the Global Action Fund for Fungal
Infections (GAFFI) (i), the Cryptococcal Meningitis Advocacy Group (CryptoMAG) (iii), and the
planned establishment of new groups focused on pneumocystosis and histoplasmosis. Whilst
CryptoMAG successfully proposed the addition of fluconosine and amphotericin B to the essential
medicines list, recent attempts to include itraconazole, a crucial drug for histoplasmosis,
talaromycosis, and aspergillosis, on the WHO(World Health Organisation)’s essential medicines list
have been unsuccessful. Furthermore, none of these AIDS-related mycoses are currently
classified as neglected tropical diseases by the WHO.

Key priorities for the future
During the meeting, there was a major focus on discussing the key priorities to move the field
forward, and 5 priorities were identified:

1. Better collaborative working structures for basic scientists and clinical researchers to
   accelerate translational medicine. The meeting itself acted as an environment in which basic
   scientists and clinical researchers intensively interacted. Promoting greater interaction in the
   future will lead to accelerated translation. The 3rd AIDS-related Mycoses Conference is planned
   in 3 years’ time.

2. Better diagnostics and improved surveillance. It is particularly apparent that without POCTs
   for the major AIDS-related mycoses these infections remain difficult to diagnose, and treat, and
   their true global burden remains very difficult to ascertain.

3. Access to established medicines, as well as development of new medicines and
   vaccines. Access in particular to fluconosine, amphotericin B, and itraconazole are particularly
   patchy, and liposomal amphotericin B (AmBisome) remains very expensive in many countries.
   Acceleration of vaccination programmes should be a key priority, but will be challenging due to
   the difficulties in eliciting immune responses in immunocompromised people.

   Whilst there are major groups working in the area of cryptococcal meningitis, better cohesion
   and extension to other AIDS-related mycoses will enable more rapid progress in this area.
5. **Extension of current advocacy groups and public engagement.** New advocacy groups are being established, based on CryptoMAG, covering histoplasmosis and pneumocystis. GAFFI is currently supporting the Kenyan government in an ambitious 5-year development program(ii).

**Concluding remarks**

Invasive fungal infections continue to be a major cause of mortality in the context of advanced HIV infection globally. The medical mycology community made significant recent progress in delivering novel diagnostic and therapeutic strategies to limit mortality from these infections, and there are some encouraging novel therapies on the horizon. However, engagement of major funding bodies and governmental and non-governmental organizations is urgently needed to enable substantial reductions in the unacceptably high morbidity and mortality from the AIDS-related mycoses.

**Resources**


ii. [http://www.gaffi.org](http://www.gaffi.org)

iii. [http://preventcrypto.org/about-us/](http://preventcrypto.org/about-us/)
References